Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II Clinical trial of lipoprotein lipase deficiency gene therapy

Human Gene Therapy

Volumn 25, Issue 3, 2014, Pages 180-188

  Ferreira, Valerie ^a   Twisk, Jaap ^a   Kwikkers, Karin ^a   Aronica, Eleonora ^b   Brisson, Diane ^c   Methot, Julie ^c   Petry, Harald ^a   Gaudet, Daniel ^c  

^a UNIQURE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; CAPSID PROTEIN; CD20 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; FAS LIGAND; GRANZYME B; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; LIPOPROTEIN LIPASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRANSCRIPTION FACTOR FOXP3;

ABSENCE OF SIDE EFFECTS; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIPID STORAGE; LYMPHOCYTIC INFILTRATION; OUTCOME ASSESSMENT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; POLYMYOSITIS; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; TRANSGENE; VIRAL GENE THERAPY;

ANTIBODIES, VIRAL; BIOPSY; CYTOTOXICITY, IMMUNOLOGIC; DEPENDOVIRUS; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; INFLAMMATION; INJECTIONS, INTRAMUSCULAR; LIPOPROTEIN LIPASE; MUSCLE, SKELETAL; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TRANSGENES;

EID: 84896320924     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.169     Document Type: Article

References (31)

1. Appleyard, S.T., Dunn, M.J., Dubowitz, V., et al. (1985). Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet 1, 361-363.
2. Aronica, E., van Kempen, A.A., van der Heide, M., et al. (2005). Congenital disorder of glycosylation type Ia: a clin-icopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol. (Berl.) 109, 433-442.
3. Arruda, V., Stedman, H., Nichols, T., et al. (2005). Regional intravascular delivery of AAV-2F.IX to skeletal muscle achieves long-term correction of hemophilia B in large animal model. Blood 105, 3458-3464.
4. Brantly, M.L., Spencer, L.T., Humphries, M., et al. (2006). Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha I-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17, 1177-1186.
5. Brantly, M.L., Chulay, J.D., Wang, L., et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. USA 106, 16363-16368.
6. Carpentier, A.C., Frisch, F., Labbé, S.M., et al. (2012). Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 97, 1635-1644.
7. Englund, P., Lindroos, E., Nennesmo, I., et al. (2001). Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am. J. Pathol. 159, 1263-1273.
8. Flotte, T.R., Trapnell, B.C., Humphries, M., et al. (2011). Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing a(1)-antitrypsin: interim results. Hum. Gene Ther. 22, 1239-1247.
9. Gaudet, D., Methot, J., Gagne, C., et al. (2011). Modifications in triglyceride-rich lipoprotein metabolism induced by ali-pogene tiparvovec (AAV1-LPLS447X gene therapy) correlate with clinical benefit in patients with lipoprotein lipase deficiency (LPLD). American Heart Association Scientific Sessions, Chicago, Illinois, November 13-17. Circulation 122, A21355.
10. Gaudet, D., Méthot, J., Déry, S., et al. (2013). Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 20, 361-369.
11. Hamann, D., Baars, P., Rep, M., et al. (1997). Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186, 1407-1418.
12. Haurigot, V., Mingozzi, F., Buchlis, G., et al. (2010). Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol. Ther. 18, 1-12.
13. Hurlbut, G., Ziegler, R., Nietupski, J., et al. (2010). Pre-existing immunity and low expression in primates highlight transla-tional challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983-1994.
14. Jiang, H., Couto, L.B., Patarroyo-White, S., et al. (2006). Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Gene Ther. 108, 3321-3328.
15. Kaplitt, M.G., Feigin, A., Tang, C., et al. (2007). Safety and tolerability of gene therapy with an adenoassociated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369, 2097-2105.
16. Manno, C.S., Chew, A.J., Hutchison, S., et al. (2003). AAV mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972.
17. Manno, C.S., Pierce, G.F., Arruda, V.R., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347.
18. Mays, L., and Wilson, J. (2011). The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther. 19, 16-27.
19. Mendell, J.R., Rodino-Klapac, L.R., Rosales-Quintero, X., et al. (2009). Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann. Neurol. 66, 290-297.
20. Miller, F.W., Love, L.A., Barbieri, S.A., et al. (1990). Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and au-toantibody subgroups. Clin. Exp. Immunol. 81, 373-379.
21. Mingozzi, F., and High, K.A. (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23-36.
22. Mingozzi, F., Hasbrouck, N.C., Basner-Tschakarjan, E., et al. (2007). Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110, 2334-2341.
23. Mueller, C., Chulay, J.D., Trapnell, B.C., et al. (2013). Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J. Clin. Invest. 123, 5310-5318.
24. Negrete, A., and Kotin, R.M. (2008). Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology. Brief Funct. Genomic Proteomic 7, 303-311.
25. Peterson, J., Fujimoto, W.Y., and Brunzell, J.D. (1992). Human lipoprotein lipase: relationship of activity, heparin affinity, and conformation as studied with monoclonal antibodies. J. Lipid Res. 33, 1165-1170.
26. Poirier, P., Marcell, T., Huey, P.U., et al. (2000). Increased intracellular triglyceride in C(2)C(12) muscle cells trans-fected with human lipoprotein lipase. Biochem. Biophys. Res. Commun. 270, 997-1001.
27. Raj, D., Davidoff, A.M., and Nathwani, A.C. (2011). Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev. Hematol. 4, 539-549.
28. Rip, J., Nierman, M.C., Sierts, J.A., et al. (2005). Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum. Gene Ther. 16, 1276-1286.
29. Rodino-Klapac, L.R., Lee, J.S., Mulligan, R.C., et al. (2008). Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology 71, 240-247.
30. Troost, D., Das, P.K., van den Oord, J.J., et al. (1992). Im-munohistological alterations in muscle of patients with amyo-trophic lateral sclerosis: mononuclear cell phenotypes and expression of MHC products. Clin. Neuropathol. 11, 115-120.
31. Walsh, C.M., Glass, A.A., Chiu, V., et al. (1994). The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J. Immunol. 153, 2506-2514.